# Biosun Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biosun-pharma

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.biosunpharma.cn
- Latest round: Series C (May 20, 2025)
- Investors on record: 4

## About

Founded in 2020 and based in Hangzhou, China, Biosun Pharma operates as a biomedical technology company that provides molecular targeting and antibody drugs for tumors,  autoimmune diseases and inflammatory diseases. The company has clinical operations branches in Hangzhou, Chengdu, Changsha, and Zhengzhou. In October 2023, it closed series B+ funding from Sinowisdom. In May 2025, Biosun Pharma closed a series C+ from new investors Hyfinity Investments and Zhejiang Yuhang Industrial Transformation & Upgrading Investment.

The company engages in the development of drugs for tumors,  autoimmune diseases, and inflammatory diseases. Its product Bangsairuini completed the phase III clinical study. Products applicable to myeloproliferative neoplasms, lymphomas and other blood diseases. Besides, it is developing Bangsatini for autoimmune diseases, such as immune thrombocytopenia (ITP), chronic immune urticaria, and chronic graft-versus-host diseases. 

The company generates revenue by doing research, development and providing molecular targeted and antibody drugs.

## Funding rounds

- Series C, May 20, 2025 — Zhejiang Yuhang Industrial Transformation & Upgrading Investment, Hyfinity Investments
- Series B, Oct 12, 2023 — Sinowisdom
- Series B, Jan 6, 2023 — Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series B
- Zhejiang Yuhang Industrial Transformation & Upgrading Investment — Series C
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Series C